Thermal inactivation of adenovirus type 5

被引:33
作者
Maheshwari, G [1 ]
Jannat, R [1 ]
McCormick, L [1 ]
Hsu, D [1 ]
机构
[1] Merck & Co Inc, Merck Res Labs, Bioproc R&D, W Point, PA 19486 USA
关键词
adenovirus; inactivation kinetics; thermal inactivation; potency assay;
D O I
10.1016/j.jviromet.2004.02.003
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Adenovirus-based products are being developed for human use as vaccine constructs and gene therapy vehicles. In order to operate by cGMP guidelines and to address biosafety concerns, it is imperative to ensure that adequate decontamination procedures are implemented in adenovirus manufacturing facilities. Liquid decontamination procedures based on heat treatment are relatively easy to employ in a manufacturing setting. In this study, we have conducted small-scale experiments to determine the effectiveness of thermal inactivation procedures on adenovirus type 5. We have determined the robustness of the assays used to measure sample potency with regard to different sample matrices and adenovirus constructs. Greater than eight logs of reduction in adenovirus type 5 potency may be obtained upon exposure of the sample to temperatures greater than 70 degreesC and times longer than 20 min. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:141 / 145
页数:5
相关论文
共 13 条
  • [1] A COMPARISON OF POLYMERASE CHAIN-REACTION AND AN INFECTIVITY ASSAY FOR HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TITRATION DURING VIRUS INACTIVATION OF BLOOD COMPONENTS
    HART, H
    MCOMISH, F
    HART, WG
    SIMMONDS, P
    YAP, PL
    [J]. TRANSFUSION, 1993, 33 (10) : 838 - 841
  • [2] Humpheson L, 1998, APPL ENVIRON MICROB, V64, P459
  • [3] THE THERMAL-STABILITY OF YELLOW-FEVER VACCINES
    ISHAK, R
    HOWARD, CR
    [J]. MEMORIAS DO INSTITUTO OSWALDO CRUZ, 1990, 85 (03): : 339 - 345
  • [4] THE HEAT INACTIVATION OF VACCINIA VIRUS
    KAPLAN, C
    [J]. JOURNAL OF GENERAL MICROBIOLOGY, 1958, 18 (01): : 58 - 63
  • [5] LEWIS J, 2001, AM SOC GEN THER 4 AN
  • [6] Non-replicating expression vectors: Applications in vaccine development and gene therapy
    Limbach, KJ
    Paoletti, E
    [J]. EPIDEMIOLOGY AND INFECTION, 1996, 116 (03) : 241 - 256
  • [7] LUFF PR, 1992, DEV BIOL STAND, V79, P155
  • [8] Mauler R, 1978, Dev Biol Stand, V41, P267
  • [9] Sofer G., 2003, BIOPHARM, V15, P28
  • [10] Sofer Gail, 1995, Current Opinion in Biotechnology, V6, P230, DOI 10.1016/0958-1669(95)80038-7